Modeling the cost-effectiveness of doubling atorvastatin's dose versus adding niacin ER

被引：0

作者：

Olson, BM

Malone, DC

机构：

来源：

FORMULARY | 2001年 / 36卷 / 10期

关键词：

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Decision-analytic models are useful tools that are helpful in making formulary decisions and comparing treatment pathways, especially when a level of uncertainty exists as to which clinical strategy is most appropriate for patients with a given health state. The purpose of this article is to provide an example of how a decision-analysis model is designed and interpreted for the treatment of coronary heart disease (CHD). A step-by-step approach to conducting decision analysis is presented so that readers can apply this technique in their own practice settings.

引用

页码：730 / +

页数：8

共 28 条

[1]

*AM HEATT ASS, 2000, 2001 HEART STROK STA

[2] Treating patients with documented atherosclerosis to national cholesterol education program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin [J].

Brown, AS ;

Bakker-Arkema, RG ;

Yellen, L ;

Henley, RW ;

Guthrie, R ;

Campbell, CF ;

Koren, M ;

Woo, W ;

McLain, R .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1998, 32 (03) :665-672

[3] Efficacy and safety of an extended-release niacin (Niaspan): A long-term study [J].

Capuzzi, DM ;

Guyton, JR ;

Morgan, JM ;

Goldberg, AC ;

Kreisberg, RA ;

Brusco, OA ;

Brody, J .

AMERICAN JOURNAL OF CARDIOLOGY, 1998, 82 (12A) :74U-81U

[4] Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].

Cleeman, JI ;

Grundy, SM ;

Becker, D ;

Clark, LT ;

Cooper, RS ;

Denke, MA ;

Howard, WJ ;

Hunninghake, DB ;

Illingworth, DR ;

Luepker, RV ;

McBride, P ;

McKenney, JM ;

Pasternak, RC ;

Stone, NJ ;

Van Horn, L ;

Brewer, HB ;

Ernst, ND ;

Gordon, D ;

Levy, D ;

Rifkind, B ;

Rossouw, JE ;

Savage, P ;

Haffner, SM ;

Orloff, DG ;

Proschan, MA ;

Schwartz, JS ;

Sempos, CT ;

Shero, ST ;

Murray, EZ .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497

[5] A multicenter, double-blind, one-year study comparing safety and efficacy of Atorvastatin versus Simvastatin in patients with hypercholesterolemia [J].

Dart, A ;

Jerums, G ;

Nicholson, G ;

dEmden, M ;

HamiltonCraig, I ;

Tallis, G ;

Best, J ;

West, M ;

Sullivan, D ;

Bracs, P ;

Black, D .

AMERICAN JOURNAL OF CARDIOLOGY, 1997, 80 (01) :39-44

[6] Comparison of one-year efficacy and safety of Atorvastatin versus Lovastatin in primary hypercholesterolemia [J].

Davidson, M ;

McKenney, J ;

Stein, E ;

Schrott, H ;

BakkerArkema, R ;

Fayyad, R ;

Black, D .

AMERICAN JOURNAL OF CARDIOLOGY, 1997, 79 (11) :1475-1481

[7] Primer on medical decision analysis .1. Getting started [J].

Detsky, AS ;

Naglie, G ;

Krahn, MD ;

Naimark, D ;

Redelmeier, DA .

MEDICAL DECISION MAKING, 1997, 17 (02) :123-125

[8]

Gardner SF, 1996, PHARMACOTHERAPY, V16, P419

[9] Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia [J].

Goldberg, A ;

Alagona, P ;

Capuzzi, DM ;

Guyton, J ;

Morgan, JM ;

Rodgers, J ;

Sachson, R ;

Samuel, P .

AMERICAN JOURNAL OF CARDIOLOGY, 2000, 85 (09) :1100-1105

[10] Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia [J].

Guyton, JR ;

Goldberg, AC ;

Kreisberg, RA ;

Sprecher, DL ;

Superko, HR ;

O'Connor, CM .

AMERICAN JOURNAL OF CARDIOLOGY, 1998, 82 (06) :737-743

← 1 2 3 →